Provided by Tiger Trade Technology Pte. Ltd.

United Therapeutics

541.60
+9.781.84%
Post-market: 541.600.00000.00%19:59 EDT
Volume:723.48K
Turnover:393.28M
Market Cap:23.74B
PE:19.44
High:549.50
Open:536.94
Low:535.95
Close:531.82
52wk High:549.50
52wk Low:266.98
Shares:43.83M
Float Shares:41.99M
Volume Ratio:1.29
T/O Rate:1.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):27.86
EPS(LYR):27.86
ROE:19.71%
ROA:12.42%
PB:3.35
PE(LYR):19.44

Loading ...

United Therapeutics EVP & General Counsel Paul A. Mahon Reports Disposal of Common Shares

Reuters
·
Oct 20, 2025

United Therapeutics Chairperson & CEO Martine A. Rothblatt Reports Disposal of Common Shares

Reuters
·
Oct 16, 2025

United Therapeutics Corporation to Announce Third Quarter 2025 Financial Results

Reuters
·
Oct 15, 2025

United Therapeutics to Present New Clinical Data on Pulmonary Hypertension and Inhaled Treprostinil at CHEST 2025 Annual Meeting

Reuters
·
Oct 13, 2025

United Therapeutics CEO Martine A. Rothblatt Reports Disposal of Common Shares

Reuters
·
Oct 11, 2025

RBC Capital Sticks to Its Buy Rating for United Therapeutics (UTHR)

TIPRANKS
·
Oct 10, 2025

BofA Cuts Price Target on United Therapeutics to $461 From $463

MT Newswires Live
·
Oct 09, 2025

United Therapeutics price target lowered to $461 from $463 at BofA

TIPRANKS
·
Oct 09, 2025

United Therapeutics CEO Martine Rothblatt Reports Disposal of Common Shares

Reuters
·
Oct 07, 2025

BTIG biotech analyst holds an analyst/industry conference call

TIPRANKS
·
Oct 04, 2025

United Therapeutics EVP & General Counsel Paul A. Mahon Reports Disposal of Common Shares

Reuters
·
Oct 03, 2025

Buy Rating for United Therapeutics Driven by Legal Positioning and Market Advantages Amid Patent Litigation

TIPRANKS
·
Oct 02, 2025

UBS Reaffirms Their Buy Rating on United Therapeutics (UTHR)

TIPRANKS
·
Oct 02, 2025

United Therapeutics Chairperson & CEO Martine A. Rothblatt Reports Disposal of Common Shares

Reuters
·
Oct 01, 2025

UBS Adjusts United Therapeutics Price Target to $580 From $560, Maintains Buy Rating

MT Newswires Live
·
Sep 29, 2025

United Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
Sep 29, 2025

United Therapeutics Corporation : H.c. Wainwright Raises Target Price to $500 From $400

THOMSON REUTERS
·
Sep 29, 2025

United Therapeutics CEO Martine Rothblatt Reports Sale of Common Shares

Reuters
·
Sep 29, 2025

United Therapeutics' Tyvaso Success in IPF to Unlock Big Market Opportunity, RBC Says

MT Newswires Live
·
Sep 26, 2025

Top Calls on Wall Street: Kenvue, Riot, CarMax, Visa and More

Tiger Newspress
·
Sep 26, 2025